NRx Pharmaceuticals Inc.
(NRXP)
undefined
undefined%
At close: undefined
1.20
0.00%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases.
Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.
The company was founded in 2015 and is based in Wilmington, Delaware.
NRx Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Dec 4, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Dr. Jonathan C. Javitt M.D., M.P.H. |
Contact Details
Address: 1201 Orange Street Wilmington, Delaware United States | |
| Website | https://www.nrxpharma.com |
Stock Details
| Ticker Symbol | NRXP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001719406 |
| CUSIP Number | 089482103 |
| ISIN Number | US6294441000 |
| Employer ID | 82-2844431 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan C. Javitt M.D., M.P.H. | Co-Founder, Chief Scientist Officer, Chairman & Interim Chief Executive Officer |
| Matthew Patrick Duffy | Chief Business Officer & Co-Chief Executive Officer of Hope Therapeutics |
| Richard Clavano Narido | Chief Financial Officer & Treasurer |
| Dr. Philip T. Lavin Ph.D. | Chief Methodologist |
| Dr. Riccardo Panicucci Ph.D. | Chief Manufacturing & Technology Officer |
| Suzanne Messere | Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2024 | 3 | Filing |
| Nov 20, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | S-1 | Filing |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 15, 2024 | 8-K | Current Report |
| Oct 11, 2024 | 8-K | Current Report |
| Sep 05, 2024 | DEF 14A | Filing |
| Aug 27, 2024 | PRE 14A | Filing |